UNRESECTABLE BREAST CARCINOMA
Clinical trials for UNRESECTABLE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat breast cancer: immune-boosting drug combos tested
Disease control OngoingThis study tests whether combining an immunotherapy drug (avelumab) with other medications can help shrink or control advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 145 adults with stage IV or recurrent triple-negative breast cancer …
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New drug combo shows promise against tough breast cancer
Disease control OngoingThis study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating. The goa…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New combo therapy aims to turn tumors against themselves in advanced cancer patients
Disease control OngoingThis early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC